Clinical Trials Browser

Phase 2 × Pancreatic Neoplasms × BI 2536 × Clear all

NCT00710710 2022-05-04

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Phase 2 Completed

89 enrolled 20 charts

Gastrointestinal

Pancreatic Neoplasms